MeSH term
Frequency | Condition_Probility | Humans | 128 | 0.0 |
Acetylcholinesterase/*metabolism | 8 | 5.0 |
Animals | 51 | 0.0 |
Brain/enzymology | 2 | 1.0 |
Butyrylcholinesterase/metabolism | 5 | 35.0 |
Dimerization | 2 | 0.0 |
In Vitro | 6 | 0.0 |
Rats | 11 | 0.0 |
Research Support, Non-U.S. Gov't | 66 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Aryldialkylphosphatase | 3 | 1.0 |
Hydrolysis | 5 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Acetylcholinesterase/metabolism | 5 | 6.0 |
Adult | 20 | 0.0 |
Aged | 28 | 0.0 |
Aged, 80 and over | 12 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Butyrylcholinesterase/*metabolism | 11 | 57.0 |
Female | 50 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 28 | 0.0 |
Adolescent | 9 | 0.0 |
Child | 7 | 0.0 |
Child, Preschool | 3 | 0.0 |
Heterozygote | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Infant | 2 | 0.0 |
Male | 51 | 0.0 |
Middle Aged | 31 | 0.0 |
Mutation | 6 | 0.0 |
Polymerase Chain Reaction | 14 | 0.0 |
Time Factors | 5 | 0.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Japan | 4 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
Pedigree | 12 | 0.0 |
Point Mutation | 5 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Comparative Study | 20 | 0.0 |
Genes | 2 | 0.0 |
Lod Score | 2 | 0.0 |
Molecular Sequence Data | 19 | 0.0 |
Age Factors | 5 | 0.0 |
Brazil/epidemiology | 2 | 2.0 |
Butyrylcholinesterase/*genetics | 17 | 62.0 |
Cholinesterases/*genetics | 3 | 27.0 |
Genotype | 16 | 0.0 |
Phenotype | 15 | 0.0 |
Regression Analysis | 2 | 0.0 |
Variation (Genetics)/*genetics | 4 | 1.0 |
Butyrylcholinesterase/blood/*metabolism | 2 | 100.0 |
English Abstract | 5 | 0.0 |
*Environmental Exposure | 2 | 2.0 |
*Organophosphorus Compounds | 4 | 13.0 |
Base Sequence | 15 | 0.0 |
Butyrylcholinesterase/*blood | 11 | 68.0 |
DNA Primers | 8 | 0.0 |
Mice | 17 | 0.0 |
Rabbits | 7 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Cholinesterase Inhibitors/*chemical synthesis/chemistry | 2 | 40.0 |
Kinetics | 21 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Stereoisomerism | 4 | 1.0 |
Apolipoproteins E/*genetics | 3 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Risk Factors | 3 | 0.0 |
Amino Acid Substitution | 7 | 0.0 |
Gene Frequency | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Reference Values | 4 | 0.0 |
*Variation (Genetics) | 6 | 0.0 |
Cholinesterase Inhibitors/pharmacology | 10 | 23.0 |
Motor Endplate/*enzymology | 2 | 40.0 |
Organ Specificity | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Tetraisopropylpyrophosphamide/pharmacology | 3 | 100.0 |
Acetylcholinesterase/*blood | 3 | 5.0 |
Enzyme Stability | 4 | 2.0 |
Reproducibility of Results | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Cholinesterase Reactivators/pharmacology | 2 | 28.0 |
Drug Interactions | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Hamsters | 8 | 0.0 |
Pyridinium Compounds/pharmacology | 2 | 25.0 |
Alleles | 5 | 0.0 |
Apolipoproteins E/genetics | 4 | 1.0 |
Butyrylcholinesterase/blood/*pharmacology | 2 | 100.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Mass Fragmentography | 2 | 0.0 |
Metabolic Clearance Rate | 2 | 0.0 |
Acetylcholinesterase/blood | 3 | 11.0 |
Cholesterol/blood | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Amino Acid Sequence | 14 | 0.0 |
CHO Cells | 5 | 0.0 |
Cell Line | 3 | 0.0 |
*Conserved Sequence | 2 | 1.0 |
Cysteine/genetics | 2 | 1.0 |
Models, Molecular | 7 | 0.0 |
Protein Conformation | 5 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Cholinesterase Inhibitors/*pharmacology | 10 | 15.0 |
Substrate Specificity | 7 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
*Gene Amplification | 2 | 0.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Poisoning/prevention & control | 2 | 66.0 |
Transfection | 4 | 0.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
Cattle | 7 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Binding Sites | 6 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Protein Binding | 3 | 0.0 |
Torpedo | 2 | 5.0 |
Cats | 3 | 0.0 |
Acetylcholinesterase/*cerebrospinal fluid | 5 | 19.0 |
Butyrylcholinesterase/*cerebrospinal fluid | 5 | 71.0 |
*Cholinesterase Inhibitors | 4 | 40.0 |
Organophosphorus Compounds/*pharmacology | 2 | 9.0 |
Organ Size | 2 | 1.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Butyrylthiocholine/metabolism | 2 | 28.0 |
Mutation/genetics | 4 | 0.0 |
Butyrylcholinesterase/blood/*genetics | 4 | 100.0 |
*Point Mutation | 3 | 0.0 |
Cocaine/*blood | 2 | 100.0 |
Half-Life | 4 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Heat | 2 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Temporal Lobe/enzymology | 2 | 25.0 |
Butyrylcholinesterase/biosynthesis/blood/*genetics | 2 | 100.0 |
Exons | 4 | 0.0 |
Fetus | 2 | 0.0 |
Fluorides/*pharmacology | 2 | 40.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Metabolic Detoxication, Drug | 2 | 2.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Cholinesterases/*metabolism | 9 | 64.0 |
Butyrylcholinesterase/*genetics/metabolism | 2 | 40.0 |
Organophosphorus Compounds/antagonists & inhibitors/*toxicity | 2 | 100.0 |
Tissue Distribution | 3 | 0.0 |
Catalysis | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Butyrylcholinesterase/*blood/*genetics | 3 | 100.0 |
DNA/blood | 2 | 1.0 |
Cholinesterases/genetics | 2 | 100.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
Acetylcholinesterase/*genetics | 3 | 15.0 |
Butyrylcholinesterase/genetics | 2 | 28.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Colorimetry | 2 | 3.0 |
Histocytochemistry | 2 | 0.0 |
Introns | 2 | 0.0 |
Cholinesterase Inhibitors/*chemistry/pharmacology | 2 | 66.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Molecular Biology | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Alzheimer Disease/*enzymology | 2 | 4.0 |
Pregnancy | 2 | 0.0 |
Aging/*metabolism | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Embryonic and Fetal Development | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Gene Library | 2 | 0.0 |
*Genetics, Population | 2 | 0.0 |
Pharmacogenetics | 2 | 1.0 |
Turkey | 2 | 1.0 |
Polymorphism, Genetic | 2 | 0.0 |
Cobalt/*pharmacology | 2 | 20.0 |
Manganese/*pharmacology | 2 | 25.0 |
Nickel/*pharmacology | 2 | 25.0 |
Membrane Proteins/genetics | 3 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Restriction Mapping | 3 | 0.0 |
DNA Probes | 2 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Rats, Inbred Strains | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Horses | 3 | 2.0 |
Lethal Dose 50 | 2 | 3.0 |
Cholinesterases/*cerebrospinal fluid | 3 | 42.0 |
Erythrocytes/enzymology | 4 | 1.0 |
Physostigmine/*analogs & derivatives/pharmacology | 2 | 50.0 |
Butyrylcholinesterase/blood | 2 | 33.0 |
Acetylcholinesterase/chemistry | 2 | 28.0 |
Butyrylcholinesterase/chemistry | 2 | 33.0 |
Molecular Conformation | 2 | 0.0 |
Cholinesterases/*analysis | 2 | 20.0 |
Brain/drug effects/enzymology | 2 | 16.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
tau Proteins/genetics | 2 | 28.0 |
